Canaccord Genuity Reiterates a 'Buy' on Anthera Pharma (ANTH); Expectations for June Phase 2 PEARL Trial

Article Stock Quotes (1) Comments (0)

Canaccord Genuity reiterates a 'Buy' on Anthera Pharma (NASDAQ: ANTH) price target of $6.00.

Analyst, Ritu Baral, said, "Reiterate rating and price target on blisibimod (B--mod) clinical and commercial potential in lupus. We expect B-mod, ANTH’s BAFF peptibody for lupus, will yield positive data from the Phase 2 PEARL trial in June and ANTH to start the Phase 3 Chablis trial in Q1/13. ANTH may start Phase 2 B-mod trials in other lupus-related B cell disorders to leverage market potential and diversify clinical risk."

For an analyst ratings summary and ratings history on Anthera Pharma click here. For more ratings news on Anthera Pharma click here.

Shares of Anthera Pharma closed at $2.32 yesterday, with a 52 week range of $2.25-$9.08.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Analyst Sees Potential for Omeros' (OMER) OMS824 as FDA Gives Clearance
• Wedbush Downgrades salesforce.com (CRM) to Neutral
• Deutsche Bank Resumes CenterPoint Energy (CNP) at Hold

Create E-mail Alert Related Categories

Analyst Comments, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?